Differential host inflammatory responses to viable versus antibiotic-killed bacteria in experimental microbial sepsis.
Staphylococcus aureus killed during imipenem or ceftazidime chemotherapy in mice elicited an early release of tumor necrosis factor alpha (TNF-alpha) into the systemic circulation. This response was coincident in time with an increase in leukocyte-endothelium adhesive interactions in the microvasculature. Equivalent responses were not observed without the antibiotic treatment (imipenem or ceftazidime). Protective efficacy of the same antibiotic treatment was markedly diminished in D-galactosamine-treated mice compared to controls; e.g., it dropped from 2,000-fold to 70-fold with 4 mg of imipenem per kg given at the time of challenge. Nevertheless, protection was quantitatively restored upon concurrent administration of neutralizing anti-TNF-alpha antibody or 4 mg of dexamethasone per kg to these TNF-alpha-hypersensitive mice. Importantly, protection afforded by dexamethasone was not seen when the animals were challenged with viable organisms but without the concurrent administration of antibiotic. An early TNF-alpha response could also be demonstrated upon challenge with Escherichia coli, but in this instance, neither the timing nor the magnitude of that response was influenced by treatment with these antibiotics. We conclude from these studies that the inflammatory response to viable versus killed bacteria may differ markedly depending on the particular bacterium, host sensitivity to TNF-alpha, and possibly the Gram stain classification.
Silverstein
R
R
Department of Biochemistry, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA. rsilvers@kumc.edu
Wood
J G
JG
Xue
Q
Q
Norimatsu
M
M
Horn
D L
DL
Morrison
D C
DC
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D002448:Cell Adhesion; D002465:Cell Movement; D002511:Cephalosporins / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000378:metabolism; D004926:Escherichia coli / Q000276:immunology*; D005260:Female; D005688:Galactosamine / Q000494:pharmacology; D015378:Imipenem / Q000494:pharmacology; D007700:Kinetics; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D051379:Mice; D008833:Microcirculation / Q000378:metabolism / Q000382:microbiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000276:immunology* / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000276:immunology*; D013845:Thienamycins / Q000494:pharmacology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D002511:Cephalosporins; D013845:Thienamycins; D014409:Tumor Necrosis Factor-alpha; D015378:Imipenem; D005688:Galactosamine; D003907:Dexamethasone; D002442:Ceftazidime